Abstract
Recent metastatic biopsy programs combined with advances in sequencing technologies have provided new insights into the genomic landscape of castration-resistant prostate cancer (CRPC), identifying actionable targets and diverse resistance mechanisms. Here, we describe the molecular features of CRPC and how these findings are being translated into the clinic. Current challenges include tumor heterogeneity, the timing and potential cooperation of multiple driver gene aberrations, and the optimal timing and use of molecular profiling in the clinic including both tissue-based and liquid biopsy biomarkers (ie, circulating tumor cells and circulating tumor DNA). We summarize potential therapeutic strategies and ongoing molecularly-driven clinical trials. This review contains 5 figures, 2 tables and 57 references Key Words: androgen receptor, biomarkers, castrate-resistant prostate cancer, DNA repair, genomics, heterogeneity, precision oncology, targeted therapy, treatment resistance
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call